Freeline Therapeutics Holdings plc - ADR

NASDAQ:FRLN  
3.96
-0.05 (-1.25%)
Earnings Announcements

Freeline Therapeutics Holdings Appoints Michael Parini As CEO

Published: 08/16/2021 11:29 GMT
Freeline Therapeutics Holdings plc - ADR (FRLN) - Freeline Appoints Michael J. Parini As Chief Executive Officer and Reports Second Quarter 2021 Financial Results.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.92

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.76

More details on our Analysts Page.